David Goblot
About David Goblot
David Goblot serves as a Principal Scientist at Celerion in Montreal, Quebec, where he specializes in phase 1 protocols for new drugs and bioequivalence studies. He has a strong academic background in Biotechnology and Physiology, and he actively guides and teaches PK Scientists.
Work at Celerion
David Goblot has been serving as a Principal Scientist at Celerion since 2010. He is based in Montreal, Quebec, Canada. In this role, he focuses on phase 1 protocols for new drugs, including first-in-human studies and drug-drug interaction studies. His responsibilities include conducting literature reviews and scientific research to support study designs and protocols. Goblot also interacts with government regulatory agencies and clients to facilitate study processes.
Education and Expertise
David Goblot has a strong educational background in the life sciences. He studied at McGill University, where he earned a Bachelor of Science in Physiology from 1984 to 1988. He furthered his education at Université de Montréal, obtaining a Graduate Diploma in Drug Development and Clinical Research from 1994 to 2004. Additionally, he achieved a Certificate in Biotechnology from the same institution, studying from 1990 to 1997. His extensive knowledge in pharmacokinetics and pharmacodynamics (PK/PD) allows him to guide and teach PK scientists effectively.
Background
David Goblot has accumulated significant experience in the pharmaceutical field, particularly in bioequivalence studies for generic drugs and biosimilars. His career spans over several years, during which he has developed a comprehensive understanding of drug development processes. His academic and professional journey has equipped him with the skills necessary to navigate complex regulatory environments and collaborate with various stakeholders in the industry.
Achievements
Throughout his career, David Goblot has contributed to the advancement of drug development through his work in phase 1 clinical trials and bioequivalence studies. He has played a key role in the design and execution of studies that support the approval of new medications. His ability to interact with regulatory agencies and clients has facilitated smoother study processes, enhancing the efficiency of drug development initiatives.